$CRSP
CRISPR Therapeutics AG

2017 Q3 Form 10-Q Financial Statement

#000156459017022720 Filed on November 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q3 2016 Q3
Revenue $2.387M $1.549M
YoY Change 54.1%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.100M $4.100M
YoY Change 97.56% 64.0%
% of Gross Profit
Research & Development $17.80M $12.05M
YoY Change 47.69% 221.47%
% of Gross Profit
Depreciation & Amortization $800.0K $200.0K
YoY Change 300.0% 640.74%
% of Gross Profit
Operating Expenses $25.96M $16.16M
YoY Change 60.63% 160.54%
Operating Profit -$23.57M -$14.61M
YoY Change 61.33% 135.57%
Interest Expense -$400.0K -$1.000K
YoY Change 39900.0% -87.5%
% of Operating Profit
Other Income/Expense, Net -$100.0K -$76.00K
YoY Change 31.58% -7700.0%
Pretax Income -$24.00M -$14.69M
YoY Change 63.42% 136.83%
Income Tax $707.0K $8.000K
% Of Pretax Income
Net Earnings -$24.71M -$14.68M
YoY Change 68.3% 131.07%
Net Earnings / Revenue -1035.06% -947.71%
Basic Earnings Per Share -$0.62 -$2.77
Diluted Earnings Per Share -$0.62 -$2.77
COMMON SHARES
Basic Shares Outstanding 40.09M 5.292M
Diluted Shares Outstanding 40.09M 5.292M

Balance Sheet

Concept 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $253.5M $228.6M
YoY Change 10.89%
Cash & Equivalents $253.5M $228.6M
Short-Term Investments
Other Short-Term Assets $1.900M $900.0K
YoY Change 111.11%
Inventory
Prepaid Expenses
Receivables $3.200M $2.092M
Other Receivables $0.00 $0.00
Total Short-Term Assets $258.6M $231.7M
YoY Change 11.63%
LONG-TERM ASSETS
Property, Plant & Equipment $19.60M $3.862M
YoY Change 407.51%
Goodwill
YoY Change
Intangibles $413.0K
YoY Change
Long-Term Investments $0.00 $35.69M
YoY Change -100.0%
Other Assets $3.800M $3.888M
YoY Change -2.26%
Total Long-Term Assets $23.70M $47.00M
YoY Change -49.58%
TOTAL ASSETS
Total Short-Term Assets $258.6M $231.7M
Total Long-Term Assets $23.70M $47.00M
Total Assets $282.3M $278.7M
YoY Change 1.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.100M $1.943M
YoY Change 8.08%
Accrued Expenses $8.500M $12.40M
YoY Change -31.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.10M $78.10M
YoY Change -84.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $91.20M $574.0K
YoY Change 15788.5%
Total Long-Term Liabilities $91.20M $574.0K
YoY Change 15788.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.10M $78.10M
Total Long-Term Liabilities $91.20M $574.0K
Total Liabilities $103.4M $155.6M
YoY Change -33.56%
SHAREHOLDERS EQUITY
Retained Earnings -$74.18M
YoY Change
Common Stock $11.73M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00
YoY Change
Treasury Stock Shares 274.2K shares
Shareholders Equity $179.0M -$62.48M
YoY Change
Total Liabilities & Shareholders Equity $282.3M $278.7M
YoY Change 1.31%

Cashflow Statement

Concept 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$24.71M -$14.68M
YoY Change 68.3% 131.07%
Depreciation, Depletion And Amortization $800.0K $200.0K
YoY Change 300.0% 640.74%
Cash From Operating Activities -$15.87M -$12.27M
YoY Change 29.34% 130.64%
INVESTING ACTIVITIES
Capital Expenditures -$2.990M -$1.510M
YoY Change 98.01% 174.55%
Acquisitions
YoY Change
Other Investing Activities -$500.0K $0.00
YoY Change
Cash From Investing Activities -$3.490M -$1.510M
YoY Change 131.13% 174.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 600.0K -4.480M
YoY Change -113.39%
NET CHANGE
Cash From Operating Activities -15.87M -12.27M
Cash From Investing Activities -3.490M -1.510M
Cash From Financing Activities 600.0K -4.480M
Net Change In Cash -18.76M -18.26M
YoY Change 2.74% 211.07%
FREE CASH FLOW
Cash From Operating Activities -$15.87M -$12.27M
Capital Expenditures -$2.990M -$1.510M
Free Cash Flow -$12.88M -$10.76M
YoY Change 19.7% 125.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-14680000
us-gaap Net Income Loss
NetIncomeLoss
-68498000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.72
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.43
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39904863
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5422617
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
3888000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
385000
CY2017Q3 crsp Research And Development Expense From Related Party
ResearchAndDevelopmentExpenseFromRelatedParty
1208000
CY2016Q3 crsp Research And Development Expense From Related Party
ResearchAndDevelopmentExpenseFromRelatedParty
361000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8051000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
11482000
CY2017Q3 us-gaap Profit Loss
ProfitLoss
-24707000
CY2016Q3 us-gaap Profit Loss
ProfitLoss
-14694000
us-gaap Profit Loss
ProfitLoss
-68498000
us-gaap Profit Loss
ProfitLoss
-40300000
CY2016Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-14000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-24000
us-gaap Net Income Loss
NetIncomeLoss
-40276000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.77
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40088718
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5292348
CY2017Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1249000
CY2016Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
385000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2218000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
513000
us-gaap Share Based Compensation
ShareBasedCompensation
11894000
us-gaap Share Based Compensation
ShareBasedCompensation
6816000
us-gaap Paid In Kind Interest
PaidInKindInterest
8050000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-28000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
9000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
7000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
4000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
2453000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
54000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1753000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
304000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
694000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2979000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2013-10-28
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Basel, Switzerland
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
118000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
246000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
61929000
crsp Noncash Contribution Of Intellectual Property To Equity Method Investee
NoncashContributionOfIntellectualPropertyToEquityMethodInvestee
36372000
crsp Issuance Costs For Initial Public Offering In Accounts Payable And Accrued Expenses
IssuanceCostsForInitialPublicOfferingInAccountsPayableAndAccruedExpenses
825000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3275000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2043000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1220000
crsp Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-903000
crsp Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
196000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
31000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
11000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-55255000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-35894000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7609000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2788000
crsp Proceeds From Contribution Of Intellectual Property To Equity Method Investee
ProceedsFromContributionOfIntellectualPropertyToEquityMethodInvestee
20000000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
500000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
100000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-8109000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
17112000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16000
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
1810000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2677000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
35000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1324000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1324000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
91454000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
39000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-20000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-62001000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
72652000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
315520000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
155961000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
253519000
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
228613000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5842856000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0200
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4624738000
CY2017Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22682000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21969000
CY2017Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3118000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
942000
CY2017Q3 us-gaap Depreciation
Depreciation
800000
us-gaap Depreciation
Depreciation
2200000
CY2016Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
500000
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4126000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2585000
CY2017Q3 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1580000
CY2016Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
996000
CY2017Q3 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
651000
CY2016Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
492000
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1281000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2715000
CY2017Q3 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
731000
CY2016Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
3372000
CY2016Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
5081000
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
116000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1079000
CY2017Q3 crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
100000
crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
1100000
CY2016Q3 crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
200000
crsp Cost Sharing Expenses Incurred
CostSharingExpensesIncurred
1000000
crsp Cost Sharing Expenses Accrued
CostSharingExpensesAccrued
500000
CY2016 crsp Cost Sharing Expenses Accrued
CostSharingExpensesAccrued
2800000
crsp Joint Venture Agreement Date
JointVentureAgreementDate
2015-12-19
CY2017Q3 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2016Q4 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2017Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16746246
CY2016Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15325607
CY2017Q2 crsp Number Of Options Approved To Be Granted
NumberOfOptionsApprovedToBeGranted
2012684
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5227000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2293000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13204000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6816000
CY2017Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
37000000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M7D
CY2017Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0290
CY2016Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0010
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0020

Files In Submission

Name View Source Status
0001564590-17-022720-index-headers.html Edgar Link pending
0001564590-17-022720-index.html Edgar Link pending
0001564590-17-022720.txt Edgar Link pending
0001564590-17-022720-xbrl.zip Edgar Link pending
crsp-10q_20170930.htm Edgar Link pending
crsp-20170930.xml Edgar Link completed
crsp-20170930.xsd Edgar Link pending
crsp-20170930_cal.xml Edgar Link unprocessable
crsp-20170930_def.xml Edgar Link unprocessable
crsp-20170930_lab.xml Edgar Link unprocessable
crsp-20170930_pre.xml Edgar Link unprocessable
crsp-ex102_310.htm Edgar Link pending
crsp-ex103_311.htm Edgar Link pending
crsp-ex104_312.htm Edgar Link pending
crsp-ex105_313.htm Edgar Link pending
crsp-ex106_314.htm Edgar Link pending
crsp-ex107_315.htm Edgar Link pending
crsp-ex311_8.htm Edgar Link pending
crsp-ex312_6.htm Edgar Link pending
crsp-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending